0.5% Liposome-encapsulated 5-aminolevulinic acid (ALA) photodynamic therapy for acne treatment

J Cosmet Laser Ther. 2011 Feb;13(1):28-32. doi: 10.3109/14764172.2011.552613. Epub 2011 Jan 21.

Abstract

Background: Photodynamic therapy using topical 5-aminolevulinic acid (ALA) has been successful in treating acne vulgaris, but sun avoidance for at least 48 hours after treatment is necessary due to the risk of post-treatment photosensitivity. Recently, a lower concentration of liposome-encapsulated 5-ALA was introduced to minimize this risk.

Objectives: To evaluate the efficacy and safety of liposome-encapsulated 0.5% 5-ALA in the photodynamic therapy of inflammatory acne and its effects on sebum secretion in Asian skin.

Methods: Thirteen Korean subjects with inflammatory acne were administered 0.5% ALA spray before photoradiation treatment. Photoradiation was performed at 3.5-6.0 J/cm(2) three times during each of two visits, performed 2 weeks apart. Improvement of acne was evaluated subjectively and objectively based on the Korean Acne Grading System. Sebum secretion was measured quantitatively at each visit.

Results: The mean reduction in acne grade at the end of the treatment was 43.2%. Of the patients, 69.2% reported improvements in subjective skin oiliness, but fewer showed objective reductions in sebum secretion as determined by the Sebumeter® SM10. No serious adverse events were observed.

Conclusion: Photodynamic therapy using liposome-encapsulated 0.5% 5-ALA improved inflammatory acne with minimal side effects in Asians.

Publication types

  • Clinical Trial

MeSH terms

  • Acne Vulgaris / drug therapy*
  • Administration, Cutaneous
  • Adult
  • Aminolevulinic Acid / administration & dosage*
  • Female
  • Humans
  • Liposomes
  • Male
  • Photochemotherapy* / adverse effects
  • Sebum / metabolism
  • Single-Blind Method
  • Statistics, Nonparametric
  • Treatment Outcome
  • Young Adult

Substances

  • Liposomes
  • Aminolevulinic Acid